Eli Lilly Eyeing More R&D Pacts in India (India)
This article was originally published in PharmAsia News
Eli Lilly plans to increase its research and development (R&D) outsourcing in India this year and sign a few more agreements with Indian pharmaceutical companies as a way to cut drug development costs. Eli Lilly signed contracting deals with Mumbai-based Nicholas Piramal in January this year and Hyderabad-based Suven Life Sciences in August 2006. Eli Lilly India managing director Sandeep Gupta says any outsourcing decisions are being made at Eli Lilly's global headquarters. (Click here for more
You may also be interested in...
With clinical failure rates rising industry-wide, a skunkworks at Lilly, called Chorus, has been trying to boost likely-to-succeed shots on goal by getting compounds to human proof-of-concept far faster and cheaper than the internal organization. Lilly's R&D group is skeptical about the program, even anxious -- one reason Chorus has teamed up with a major venture fund to get more molecules to test. If the program works, will Lilly embrace it - or will its venture partner reap the rewards?
Celltrion's Truxima has become the first rituximab biosimilar, and just the second biosimilar overall, to be prequalified by the World Health Organization.
Fresenius Kabi’s Idacio biosimilar adalimumab rival to Humira will from the start of June be marketed in Germany by Medac, following a deal between the two companies.